Condition
Malignant Peripheral Nerve Sheath Tumor (MPNST)
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Recruiting2
Not Yet Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05642455Phase 1Recruiting
SPEARHEAD-3 Pediatric Study
NCT06849986Phase 2Recruiting
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
NCT06735820Phase 1Not Yet RecruitingPrimary
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
NCT04811196Phase 1Completed
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
Showing all 4 trials